ProShare Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-11,786
| Closed | -$49.5K | – | 1960 |
|
|
2023
Q1 | $49.5K | Sell |
11,786
-1,099
| -9% | -$5.7K | ﹤0.01% | 1671 |
|
|
2022
Q4 | $77.4K | Buy |
12,885
+1,847
| +17% | +$10.1K | ﹤0.01% | 1694 |
|
|
2022
Q3 | $64K | Buy |
11,038
+633
| +6% | +$3.94K | ﹤0.01% | 1633 |
|
|
2022
Q2 | $62K | Buy |
+10,405
| New | +$53.3K | ﹤0.01% | 1677 |
|
|
2016
Q2 | – | Sell |
-2,824
| Closed | -$15K | – | 1656 |
|
|
2016
Q1 | $15K | Sell |
2,824
-255
| -8% | -$2.04K | ﹤0.01% | 1580 |
|
|
2015
Q4 | $38K | Buy |
3,079
+1,511
| +96% | +$20.2K | ﹤0.01% | 1684 |
|
|
2015
Q3 | $23K | Sell |
1,568
-508
| -24% | -$8.78K | ﹤0.01% | 1428 |
|
|
2015
Q2 | $40K | Sell |
2,076
-821
| -28% | -$15.8K | ﹤0.01% | 1617 |
|
|
2015
Q1 | $52K | Sell |
2,897
-323
| -10% | -$7.27K | ﹤0.01% | 1866 |
|
|
2014
Q4 | $76K | Sell |
3,220
-2,109
| -40% | -$48.8K | ﹤0.01% | 1882 |
|
|
2014
Q3 | $129K | Sell |
5,329
-1,208
| -18% | -$31.4K | ﹤0.01% | 2124 |
|
|
2014
Q2 | $184K | Sell |
6,537
-6,614
| -50% | -$199K | ﹤0.01% | 2208 |
|
|
2014
Q1 | $447K | Buy |
+13,151
| New | +$449K | 0.01% | 1954 |
|
|
2013
Q4 | – | Sell |
-7,115
| Closed | -$117K | – | 2481 |
|
|
2013
Q3 | $117K | Buy |
+7,115
| New | +$82.4K | ﹤0.01% | 2377 |
|
Other funds holding CTIC
ProShare Advisors's CTIC Position: Q2 2023 in Review
ProShare Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 11,786 shares — an estimated $49.5K sold.
ProShare Advisors first reported a position in CTIC in Q3 2013 and held it in 14 quarters. The position peaked at $447K in Q1 2014. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- ProShare Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- ProShare Advisors sold 11,786 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $49.5K.
- ProShare Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 14 quarters.
- ProShare Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $447K in Q1 2014.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.